Hematology

CTCL is a rare type of non-Hodgkin lymphoma, primarily presenting in the skin but with extracutaneous involvement in some patients. Around…

Haematologic malignancies are a heterogeneous group of cancers, which include leukaemia, lymphoma, and multiple myeloma. These diseases are…

Ajay Kakkar opened this virtual meeting by discussing the history of the treatment and prevention of thrombosis…

Rachel Kesse-Adu highlighted that the hallmark of sickle cell disease (SCD) is painful vaso-occlusive crises (VOCs). These not only cause…

In recent years, there has been an increasing appreciation of the role that patient characteristics such as age, gender…

Although approximately 60% of patients with diffuse large B-cell lymphoma (DLBCL) can be cured, the remaining 40% have relapsed or refractory disease (R/R DLBCL). Substantial unmet need remains for effective, safe therapies for these patients. Novel targeted approaches to the treatment of R/R DLBCL include CD19-directed antibodies, antibody–drug conjugates, bispecific monoclonal antibodies, and anti-CD-19 chimeric antigen receptor (CAR) T-cell therapies.

The COVID-19 outbreak, first identified in the Wuhan district of China in December 2019, was declared a pandemic by the World Health…

At the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held virtually, data on the efficacy…